Document is current
Any future updates will be listed below
-
Authors
Lei, Katherine
Patel, Meera J.
Liu, Jialiang
Rathod, Rutu Aniruddha
von Itsztein, Mitchell S.
Fattah, Farjana J.
Mu-Mosley, Hong
SoRelle, Jeffrey A.
Park, Jason Y.
Xie, Yang
Hughes, Amy E.
Kitzman, Heather
Gerber, David E. https://orcid.org/0000-0002-7812-6741
-
Funding
Funding for this research was provided by:
Dean’s Scholar in Clinical Research Program at the University of Texas Southwestern Medical Center
National Institute of Allergy and Infectious Diseases (1U01AI156189-01)
American Cancer Society-Melanoma Research Alliance Team Award (MRAT-18-114-01-LIB)
V Foundation Robin Roberts Cancer Survivorship Award (DT2019-007)
University of Texas Lung Cancer Specialized Program of Research Excellence (SPORE (P50CA070907-21)
Harold C. Simmons Comprehensive Cancer Center Biomarker Research Core and Data Sciences Shared Resource (1P30 CA 142543-03)
- License Information
-
More Information
Article History
Received: 17 July 2025
Accepted: 15 December 2025
First Online: 27 January 2026
Declarations
:
: Jason Y. Park reports serving as co-founder and Chief Scientific Officer of OncoSeer Diagnostics, Inc. David E. Gerber reports consulting fees from Catalyst Pharmaceuticals; research funding from AstraZeneca, Karyopharm, and Novocure; participating in advisory boards for Astra-Zeneca, Elevation Oncology, Janssen Scientific Affairs, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, and Sanofi; participating in data and safety monitoring boards for Daiichi-Sankyo and Summit Therapeutics; stock shares in Gilead; U.S. patent 11,747,345; pending patents 17/045,482, 18/504,868, 63/386,387, 63/382,972, and 63/382,257; and serving as co-founder and Chief Medical Officer of OncoSeer Diagnostics, Inc.
